Akeso Doses First Patient in Landmark Phase II Trial Evaluating Novel AK146D1 and Ivonescimab Combination for Advanced Breast Cancer
Executive Overview In a significant milestone for next-generation oncology drug development, biopharmaceutical innovator Akeso has announced the successful dosing of the first patient in a pivotal Phase II clinical trial.…